Suppliers

This company was founded in 2005 in Lyon, France, after closing the Schering Plough Laboratory of Immunologicals Research (LIR). Dendritics has the exclusive License from Schering-Plough (Kenilworth-USA) to manufacture and to sell their monoclonal antibodies for research and diagnostic.
Dendritics is specialized in monoclonal antibodies to analyze dendritic cell biology.
OriGene Technologies distributes their products within Germany since several years now.

Die Firma Dendritics wurde 2005 nach der Schließung der Schering Plough Laboratory of Immunologicals Research (LIR) gegründet und hat Ihren Firmensitz in Lyon, Frankreich. Dendritics besitzt exklusiv die Lizenzen von Schering-Plough (Kenilworth-USA), um deren monoklonale Antikörper für die Forschung und Diagnostik weiter zu produzieren.
Dendritics ist, wie der Name impliziert, spezialisiert auf die Herstellung monoklonaler Antikörper für den Bereich der dendritischen Zellbiologie.
OriGene Technologies vertreibt die Produkte von Dendritics bereits seit einigen Jahren innerhalb Deutschlands.

OriGene Technologies was founded as a research tool company focused on the creation of the largest commercial collection of full-length human cDNAs in a standard expression vector. OriGene's vision is to prepare comprehensive, genome wide research tools and technology platforms to enable scientists to study complete biological pathways, thus enabling a better understanding of disease mechanisms including cancer and stem cell research. OriGene Technologies uses high-throughput, genome wide approach to develop products for pharmaceutical, biotechnology, and academic research.
Besides a searchable gene bank of over 30,000 human full-length TrueClone cDNA collection, OriGene has developed the largest offering of full length human proteins expressed in mammalian cells, ideal for functional studies. OriGene initiated the TrueMAB project to develop mouse monoclonal antibodies against protein antigens with the goal to provide protein assays for every human protein and has has produced an extensive array of ultra-specific monoclonal antibodies called UltraMAB®, which offer a unique solution to the critical issue of antibody specificity, especially for diagnostic and therapeutic antibodies.
OriGene has aquired Acris Antibodies in September 2015 to strengthen their antibody portfolio and to meet the increasing demand from European distributors and customers for faster and direct service.